National Joint Registry - Data Management, Solutions, Statistical Analysis, Reporting & Associated Services

What the buyer is asking for

The contract will initially be delivered for Northern Ireland, Wales, England, Isle of Man, Jersey, Guernsey - both NHS and Independent sector hospitals, for a period of 5 years, at a maximum total budget of up to £14,580,000 GBP including VAT, £12,150,000 GBP excluding VAT. Bids exceeding this limit will be rejected. There is potential to extend the contract for up to two additional years at a potential value of £2,916,000 GBP per year including VAT, £2,430,000 GBP per year excluding VAT. These extension values are based on no aspirational intent being invoked and are therefore subject to increase proportionally to the contract value if aspiration intent is invoked. All pricing submissions must be in regard to this 'core' value, and not inclusive of any extension costs or aspirational intent costs, i.e. Please only submit a cost schedule up to the maximum core value of £14,580,000 GBP including VAT, £12,150,000 GBP excluding VAT. The maximum budget ‘core’ value excludes the potential two year extension and aspirational intent as described in section C of Annex A – Service Specification Please note, there is no commitment by the Authority at this stage to include any aspirational intent measures. Taking the total of this aspirational intent into account, as well as the possibility that a contract extension may be offered for an additional two years, the potential ceiling value is £44,027,892 GBP including VAT, £36,689,910 GBP excluding VAT There is also a potential that the contract price will be subject to discretionary inflationary uplifts. About the National Joint Registry The National Joint Registry (NJR) is the largest orthopaedic joint replacement registry in the world. It collects, analyses and reports information on joint replacement procedures to improve patient safety, support clinical decision-making, monitor implant performance and improve the quality of care across the UK and Crown Dependencies. Joint replacement surgery is one of the most successful interventions in modern healthcare, restoring mobility and reducing pain for hundreds of thousands of patients. The NJR plays a critical role in monitoring the long-term performance of joint replacement implants and surgical techniques, providing robust evidence to clinicians, healthcare organisations, regulators, patients and the orthopaedic device industry. The NJR was established in April 2002 by the Department of Health and the Welsh Government following recommendations arising from the National Audit Office investigation into the failure of the 3M Capital Hip System. Operational responsibility for the Registry transferred to the Healthcare Quality Improvement Partnership (HQIP) on 1 April 2008. The Registry has progressively expanded its scope, collecting: •hip and knee replacement data since April 2003; •ankle replacement data since April 2010; and •shoulder and elbow replacement data since April 2012. The geographical coverage of the Registry has also expanded to include: •Northern Ireland (2013); •the Isle of Man (2015); and •Guernsey (2019). •Jersey (2025) Today, the NJR contains data relating to millions of joint replacement procedures and continues to expand annually. It is recognised internationally as a leading clinical registry and provides an essential evidence base for improving outcomes, supporting research, informing procurement decisions and identifying patient safety concerns at the earliest opportunity. The NJR is funded primarily through an annual subscription model based on eligible joint replacement procedures undertaken by NHS organisations and independent healthcare providers across participating nations. Since 2014, the orthopaedic device industry has also contributed through an annual subscription supporting supplier feedback services and related reporting. Income is managed by HQIP through a dedicated NJR fund under the governance of the NJR Board. The Healthcare Quality Improvement Partnership (HQIP) is procuring a Supplier to deliver data collection, management and technology and statistical analysis and reporting. The successful Supplier will be responsible for the secure operation, maintenance and continuous development of the NJR's data management technology services and statistical analysis supporting one of the world's largest orthopaedic registries and enabling the delivery of high-quality information to patients, clinicians, healthcare providers, commissioners, regulators, researchers and the orthopaedic industry. The procurement comprises: •Core Services •NJR data collection, data management and technology solutions; statistical analysis and reporting services. HQIP is seeking a strategic delivery partner that can demonstrate: •proven expertise in delivering secure, resilient and scalable data services; •a collaborative and solution-focused approach to partnership working; •innovation and a commitment to continuous service improvement; •responsiveness, flexibility and excellent customer service; •strong governance, information security and regulatory compliance; •the ability to identify opportunities to improve efficiency, data quality and user experience; and •effective communication and stakeholder engagement. The successful Supplier will be expected to work collaboratively with HQIP to ensure seamless delivery of the Registry, maintaining continuity of service whilst supporting future innovation and development. Over the lifetime of the Contract, the Authority's ambitions include: •improving the quality, completeness and timeliness of data collection, validation and submission processes; •enhancing the resilience, scalability, performance and security of the Registry's technology platform; •increasing interoperability with NHS systems, national datasets and other relevant health and care services through open standards and modern APIs; •improving user experience through intuitive digital services, enhanced reporting capabilities and greater self-service functionality for stakeholders; •supporting more timely reporting, surveillance, analytics and insight generation to improve patient safety, clinical outcomes and service performance; •enabling the responsible adoption of automation, advanced analytics and emerging technologies, including artificial intelligence where appropriate and compliant with legal, ethical and information governance requirements; •strengthening cyber resilience, business continuity and operational sustainability; •supporting collaborative working across healthcare providers, patients, regulators, researchers, industry and other registries; •maintaining flexibility to adapt to future changes in clinical practice, regulatory requirements and national health policy; and •ensuring the Registry remains a leading international example of excellence in clinical registry management and medical device surveillance. The scope of services includes: •Collection, processing and management of registry data through direct data entry, system interfaces and other approved data submission mechanisms; •Secure hosting, storage and management of NJR data and associated information assets; •Data validation, cleansing, quality assurance and reconciliation processes to maximise data accuracy, completeness and credibility; •Data linkage, comparison and reconciliation with relevant national and international datasets; •Development, operation and enhancement of continuous monitoring and surveillance systems, including implant and patient outcome monitoring; •Statistical analysis and reporting services, including: ooutlier detection and monitoring; odevelopment and maintenance of statistical methodologies; oanalysis supporting patient safety, clinical effectiveness and service improvement; oproduction of datasets and content for the NJR Annual Report; and odelivery of ad hoc analyses and data requests as required; •Production, publication and dissemination of reports, dashboards, datasets and stakeholde

How this is scored

Published by the buyer. A winning response is written to these weightings, not to the question.

• 11%qualitySERVICE DELIVERY MODEL, MOBILISATION, TRANSITION AND EXIT
• 11%qualityDATA COLLECTION
• 6%qualityTECHNOLOGY PLATFORM AND SOLUTION ARCHITECTURE, SECURITY AND RESILIENCE
• 5%qualitySYSTEM DEVELOPMENT, CHANGE AND RELEASE MANAGEMENT
• 11%qualitySTATISTICAL ANALYSIS, CLINICAL SURVEILLANCE AND OUTLIER MANAGEMENT
• 4%qualityCLINICAL LEADERSHIP AND OVERSIGHT
• 4%qualityPROJECT AND PROGRAMME MANAGEMENT
• 4%qualityINFORMATION GOVERNANCE
• 3%qualityCUSTOMER SUPPORT, STAKEHOLDER ENGAGEMENT AND TRAINING
• 2%qualityPERFORMANCE MANAGEMENT AND CONTINUOUS IMPROVEMENT
• 4%qualityREPORTING, DATA PRODUCTS AND STAKEHOLDER SERVICES
• 2%qualityINNOVATION AND ARTIFICIAL INTELLIGENCE
• 3%qualityINFORMATION GOVERNANCE, DATA ACCESS AND REGULATORY SUPPORT
• 20%priceCOST & ALLOCATION OF BUDGET
• 10%qualitySOCIAL VALUE

How contested is this?

Buyers publish how many bids they received. Across 72 comparable procurements we can tell you the typical field size, how often one of these goes uncontested, and whether the buyer awards on price or on quality.

Timeline

4 published dates · Europe/London

1. Tender notice published43 days ago

   10 Aug 2026, 12:29 BST
2. Clarification questions byin 3 days

   25 Sept 2026, 12:00 BST
3. Submission deadlinein 22 days

   14 Oct 2026, 12:00 BST
4. Award decision expected byin 114 days

   13 Jan 2027, 23:59 GMT

Commercial outcome and contract awards

Nothing awarded yet

Notice history

2 events · 2 releases on Find a Tender

1. Pipeline or early engagement notice15 May 2026, 11:09 BST044829-2026
2. Tender notice10 Aug 2026, 12:29 BST075692-2026

Payment terms

Payment will be made quarterly in arrears as described in the provider terms (Annex B). Disputed invoices will be dealt with as described in the provider terms (Annex B)

Documents

• Tender notice on Find a Tender